Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Semapimod. Cytokine.

Shanthi V Sitaraman1, Marouf Hoteit, Andrew T Gewirtz

  • 1Division of Digestive Diseases, Emory University School of Medicine, 615 Michael Street, Whitehead Research Bldg, Rm 205F, Atlanta, GA 30322, USA. ssitar2@emory.edu

Current Opinion in Investigational Drugs (London, England : 2000)
|February 5, 2004
PubMed
Summary

Semapimod (CNI-1493), a novel cytokine inhibitor, is being developed for inflammatory conditions like Crohn's disease. Early studies show safety, with ongoing trials for Crohn's disease and psoriasis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gut segmented filamentous Bacteria impedes growth of B16F10 subcutaneous tumors via modulating T cell function.

Mucosal immunology·2026
Same author

Soil-derived microbiota induces T regulatory cells and protect against mouse colitis, metabolic disease, and sepsis.

Gut microbes·2026
Same author

Elevated Circulating Bile Acids Driven Erythrocyte Osmotic Resistance Marks Hepatobiliary Disease.

American journal of physiology. Gastrointestinal and liver physiology·2026
Same author

Maternal Aflatoxin Exposure, Birth Outcomes, and Infant Growth in Uganda.

The American journal of tropical medicine and hygiene·2026
Same author

Microbial metabolite Enterobactin impairs mitochondrial respiration and alleviates colitis.

Gut microbes·2026
Same author

Wheat fiber mitigates colitis via non-SCFA microbial metabolite-trained intestinal macrophages.

Science advances·2026

Area of Science:

  • Pharmacology
  • Immunology
  • Drug Development

Background:

  • Semapimod (CNI-1493) is a synthetic guanylhydrazone developed by Cytokine PharmaSciences.
  • It functions as both a cytokine inhibitor and a mitogen-activated protein kinase (MAPK) blocker.
  • The compound is being investigated for its therapeutic potential in inflammatory diseases.

Purpose of the Study:

  • To evaluate the safety and efficacy of semapimod (CNI-1493) as a treatment for inflammatory conditions.
  • To explore the potential of semapimod in treating Crohn's disease, psoriasis, congestive heart failure, and pancreatitis.

Main Methods:

  • Phase I clinical trials were conducted to assess the safety profile of semapimod.
  • Phase II clinical trials are ongoing to evaluate efficacy in patients with Crohn's disease and psoriasis.
  • Preclinical and early clinical studies are being performed for other indications.

Main Results:

  • Phase I studies successfully demonstrated the safety of semapimod (CNI-1493).
  • Ongoing Phase II trials are investigating its therapeutic effects in specific inflammatory conditions.
  • Early-stage research is exploring a broader range of potential applications.

Conclusions:

  • Semapimod (CNI-1493) shows promise as a potential therapeutic agent for various inflammatory diseases.
  • Further clinical investigation is warranted to establish its efficacy and safety across different indications.
  • The development of semapimod represents a potential advancement in managing inflammatory conditions.

Related Experiment Videos